Edgewise Therapeutics (EWTX) Income from Continuing Operations (2020 - 2026)

Edgewise Therapeutics has disclosed Income from Continuing Operations across 7 years of filings, most recently posting 49013000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 49013000.0, down 20.14% year-over-year; the trailing twelve-month figure through Mar 2026 was 176010000.0 (down 20.48% YoY), and the FY2025 annual result was 167795000.0, down 25.4% from the prior year.
• Income from Continuing Operations came in at 49013000.0 for Q1 2026 at Edgewise Therapeutics, up from 50216000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 14660000.0 in Q1 2022 to a low of 50216000.0 in Q4 2025.
• The 5-year median for Income from Continuing Operations is 30143000.0 (2023), against an average of 30495529.41.
• Across the five-year window, Income from Continuing Operations tumbled 115.11% in 2022 and dropped 14.66% in 2025, its largest moves.
• Edgewise Therapeutics' Income from Continuing Operations stood at 19415000.0 in 2022, then sank by 55.26% to 30143000.0 in 2023, then plunged by 31.58% to 39662000.0 in 2024, then declined by 26.61% to 50216000.0 in 2025, then grew by 2.4% to 49013000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 49013000.0 (Q1 2026), 50216000.0 (Q4 2025), and 40666000.0 (Q3 2025), per Business Quant data.